Darunavir/ritonavir (400/50mg) fixed-dose combination (DRV/r)
Tools and resources to support national HIV programs, implementing partners, and community advocates in decision-making regarding DRV/r implementation for use in second-line treatment.
Darunavir (DRV) is a best in class protease inhibitor commonly used in high income markets, and has recently been prequalified by the WHO as a fixed dose combination with ritonavir (RTV) at a price of US $17.50/pack for use in 2L in LMICs. CHAI is pleased to share a set of resources to support national decision-making on and implementation for the optimal product. Please contact HIVToolkit@clintonhealthaccess.org with any questions about the resources listed here.
Click on a tile to view the latest resources
Product Adoption Resources
Pricing, Quantification, and Monitoring Resources
Press and Announcements
Pricing, Quantification & Monitoring Resources
Press & Announcements
Announcements, press releases, and articles related to updates on DRV/r.